Direct-acting antivirals for the treatment of chronic hepatitis C: Open issues and future perspectives

The Scientific World Journal

Volumn 2013, Issue , 2013, Pages

  Chae, Hee Bok ^a   Park, Seon Mee ^a   Youn, Sei Jin ^a  

^a Chungbuk National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACH 2864; ALISPORIVIR; ANTIVIRUS AGENT; ASUNAPREVIR; BMS 791325; BOCEPREVIR; DACLATASVIR; FALDAPREVIR; MERICITABINE; MK 5172; NECEPREVIR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG; VANIPREVIR;

ALGORITHM; ANEMIA; ANOREXIA; ANTIVIRAL THERAPY; CHRONIC HEPATITIS; CLINICAL TRIAL; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; GASTROINTESTINAL TOXICITY; GENOTYPE; HEPATITIS C; HUMAN; HYPERBILIRUBINEMIA; NEPHROTOXICITY; NONHUMAN; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URIC ACID BLOOD LEVEL; VIRUS RESISTANCE; CLASSIFICATION;

HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; HEPATITIS C, CHRONIC; HUMANS;

EID: 84879290204     PISSN: None     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2013/704912     Document Type: Review

References (35)

1. Stedman C. A., Current prospects for interferon-free treatment of hepatitis C in 2012. Journal of Gastroenterology and Hepatology 2013 28 38 45
2. McGovern B., Abu Dayyeh B., Chung R. T., Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. Hepatology 2008 48 1700 1712
3. U.S Food and Drug Administration. FDA news release. FDA approves Incivek for hepatitis C, May 2011, http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm256299.htm
4. U.S Food and Drug Administration. FDA news release. FDA approves Incivek for hepatitis C, May 2011, http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm255390.htm
5. Vectrelis (boceprevir) capsules. Merck. May 2011, http://www.accessdata. fda.gov/drugsatfda-docs/label/2011/202258lbl.pdf
6. Incibek (telaprevir) film coated tablets. Vertex. May 2011, http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/201917lbl.pdf
7. Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., Telaprevir for previously untreated chronic hepatitis C virus infection. New England Journal of Medicine 2011 364 25 2405 2416 2-s2.0-79959438789 10.1056/NEJMoa1012912
8. Sherman K. E., Flamm S. L., Afdhal N. H., Response-guided telaprevir combination treatment for hepatitis C virus infection. New England Journal of Medicine 2011 365 11 1014 1024
9. Zeuzem S., Andreone P., Pol S., Lawitz E., Diago M., Roberts S., Focaccia R., Younossi Z., Foster G. R., Horban A., Ferenci P., Nevens F., Müllhaupt B., Pockros P., Terg R., Shouval D., Van Hoek B., Weiland O., Van Heeswijk R., De Meyer S., Luo D., Boogaerts G., Polo R., Picchio G., Beumont M., Telaprevir for retreatment of HCV infection. New England Journal of Medicine 2011 364 25 2417 2428 2-s2.0-79959381354 10.1056/NEJMoa1013086
10. Poordad F., McCone J., Bacon B. R., Bruno S., Manns M. P., Sulkowski M. S., Jacobson I. M., Reddy K. R., Goodman Z. D., Boparai N., DiNubile M. J., Sniukiene V., Brass C. A., Albrecht J. K., Bronowicki J. P., Boceprevir for untreated chronic HCV genotype 1 infection. New England Journal of Medicine 2011 364 13 1195 1206 2-s2.0-79953173221 10.1056/NEJMoa1010494
11. Pearlman B. L., Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infectious Diseases 2012 12 717 728
12. Bacon B. R., Gordon S. C., Lawitz E., Marcellin P., Vierling J. M., Zeuzem S., Poordad F., Goodman Z. D., Sings H. L., Boparai N., Burroughs M., Brass C. A., Albrecht J. K., Esteban R., Boceprevir for previously treated chronic HCV genotype 1 infection. New England Journal of Medicine 2011 364 13 1207 1217 2-s2.0-79953176289 10.1056/NEJMoa1009482
13. Manns M. P., Gane E., Rodriguez-Torres M., Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C: a randomized phase II study. Hepatology 2012 56 3 884 893 10.1002/hep.25743
14. Fried M., Buti M., Dore G. J., TMC435 in combination with peginterferon and ribavirin in treatment naïve HCV genotype 1 patients: final analysis of the PILLAR phase II b study. Proceedings of the 62nd Annual Meetgin of the American Assoication for the Study of Liver Diseases November 2011 San Francisco, Calif, USA Abstract LB-5
15. Lenz O., Fevery B., Vijgen L., TMC 435 in patients infected with HCV genotype 1 who have failed previous pegylated interferon/ribavirin treatment: virologic analysis of the ASPIRE trial. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver April 2010 Barcelona, Spain Abstract 9
16. Lok A. S., Gardiner D. F., Lawitz E., Preliminary study of two antiviral agents for hepatitis C genotype 1. New England Journal of Medicine 2012 366 3 216 224 10.1056/NEJMoa1104430
17. Sulkowski M. S., Asselah T., Ferenci P., Treatment with the 2nd generation HCV PI BI 201335 results in high and consistent SVR rates-results from SILEN-C1 in treatment naïve patients across different baseline factors. Hepatology 2011 54 supplement 473A
18. Zeuzem S., Soriano V., Asselah T., Interferon (IFN)-free combination treatment with HCV NS3/4A protease inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127 +/- ribavirin (R): final results of SOUND-C2 and predictors of response. Hepatology 2012 56 supplement 308A 309A
19. Zeuzem S., Asselah T., Angus P., Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection. Gastroenterology 2011 141 6 2047 2055 10.1053/j.gastro.2011.08. 051
20. Hassanein T., Lawitz E., Crespo I., Once daily sofosbuvir (GS-7977) plus PEG/RBV: high early response rates are maintained during post-treatment follow-up in treatment-naïve patients with HCV genotype 1,4, and 6 infection in the ATOMIC study. Hepatology 2012 56 supplement 307A
21. Gane E. J., Stedman C. A., Hyland R. H., Sorensen R. D., Symonds W. T., Hindes R., Berrey M. M., Once daily GS-7977 plus ribavirin in HCV genotype 1-3: the ELECTRON. Hepatology 2012 56 supplement 306 37A
22. Pockros P., Jensen D., Tsai N., SVR-12 among G1/4 treatment-naïve patients receiving mericitabine in combination with peg-IFNa-2A7RBV: interim analysis from the JUMP-C study. Journal of Hepatology 2012 56 supplement 477 478
23. Gane E. J., Roberts S. K., Stedman C. A. M., Angus P. W., Ritchie B., Elston R., Ipe D., Morcos P. N., Baher L., Najera I., Chu T., Lopatin U., Berrey M. M., Bradford W., Laughlin M., Shulman N. S., Smith P. F., Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. The Lancet 2010 376 9751 1467 1475 2-s2.0-78049527728 10.1016/S0140-6736(10)61384-0
24. Gane E. J., Interferon-free treatment with a combination of merivitabine and danoprevir/r with or without ribavirin in treatment naïve HCV genotype 1 infected patients. Journal of Hepatology 2012 56 supplement 555 556 10.1002/hep.25651
25. Everson G. T., Sims K. D., Rodriguez-Torres M., An interferon-free, ribavirin-free 12-week regimen of daclatasvir (DCV), asunaprevir (ADV), and BMS-791325 yielded SVR4 of 94% in treatment-naïve paeitns with genotype(GT) 1 chronic hepatitis C viru (HCV) infection. Hepatology 2012 56 supplement LB3
26. Foster G. R., Hezode C., Bronowicki J. P., Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011 141 3 881 889 10.1053/j.gastro.2011.05.046
27. Pharmasset Inc, Pharmasset announces the expansion of the ELECTRON trial in chronic hepatitis C. Press release. June 2011
28. Lalezari J., Lawitz E., Rodriguez-Torres M., Once daily PSI-7977 PegIFN/RBV in a phase 2b trial: rapid virologic suppression in treatment-naive patients with G2/G3. Journal of Hepatology 2011 54 s28
29. Andriulli A., Mangia A., Iacobellis A., Ippolito A., Leandro G., Zeuzem S., Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Alimentary Pharmacology and Therapeutics 2008 28 4 397 404 2-s2.0-47749115740 10.1111/j.1365-2036.2008. 03763.x
30. Manns M., Reesink H., Berg T., Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial. Antiviral Therapy 2011 16 7 1021 1033 10.3851/IMP1894
31. Summa V., Ludmerer S. W., McCauley J. A., Fandozzi C., Burlein C., Claudio G., MK-5172, a selective inhibitor of hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants. Antimicrobial Agents and Chemotherapy 2012 56 8 4161 4167
32. Huang M., Podos S., Patel D., ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants. Hepatology 2010 52 supplement 1204A
33. Kowdley K. V., Lawitz E., Poordad F., A 12-week interferon-free treatment regimen with ABT-450/r, ABT-267, ABT-333 and ribavirin achieves SVR rates (observed data) of 99% in treatment-naïve patients and 93% in prior null responders with HCV genotype 1 infection. Hepatology 2012 56 supplement LB1
34. Sulkowski M. S., Gardiner D. F., Rodriguez-Torres M., High rate of sustained virologic response with the all-oral combination fo daclatasvir (NS5A inhibitor) plus sofosbuvir (nucleotide NS5B inhibitor), with or without ribavirin, in treatment-naïve paeitns chronically infected with HCV genotype 1,2, or 3. Hepatology 2012 56 supplement LB2
35. Ramanchandran P., Fraser A., Agrawal K., UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Alimentary Pharmacology &Therapeutics 2012 35 647 662 10.1111/j.1365-2036.2012.04992.x